Login

Financial Snapshot

Revenue
TTM
$2.902B
Gross Margin
TTM
54.31%
Net Income
TTM
$239.7M
Current Assets
2026 Q2
Current Liabilities
2026 Q2
Current Ratio
2026 Q2
171.83%
Total Assets
2026 Q2
Total Liabilities
2026 Q2
Book Value
2026 Q2
$7.183B
Cash
2026 Q2
P/E
TTM
46.73
Free Cash Flow
TTM
$492.7M

Stock Price

Loading...
Market Cap: $11.2 Billion

About Revvity Inc

Revvity Inc (NYSE: RVTY) is a life sciences and diagnostics company that develops and sells products, services, and solutions serving scientific research and clinical diagnostics markets. Revenue is generated across two reported segments, Life Sciences and Diagnostics, through a combination of instrument sales, reagent and consumable sales, and service offerings. The company grows through internal research and development investment as well as strategic acquisitions and licensing of technology. Revvity's fiscal year ended December 28, 2025, as reported in its 10-K filed February 24, 2026. The company's stated strategy includes expanding its global product and service offerings across both segments, pursuing mergers and acquisitions, and advancing artificial intelligence applications within its product portfolio and internal operations. Capital allocation priorities include organic investment, acquisitions, and opportunistic share repurchases.

Revenue model
Transactional and recurring revenue from instrument sales, consumables, reagents, and services across two segments: Life Sciences and Diagnostics. Growth is augmented through acquisitions and licensing (per 10-K, filed 2026-02-24).
Products and services
Products and services across Life Sciences and Diagnostics segments, including instruments, reagents, consumables, and associated services. Specific product names are not detailed in the available filing excerpts.
Customers and end markets
Customers in scientific research and clinical diagnostics. End markets include life sciences research and diagnostics, with a focus on high-growth markets as stated in the FY2025 10-K.
Value-chain role
Product developer and manufacturer supplying instruments, reagents, consumables, and services to research and diagnostics end users.
Geographic exposure
Global operations with international product and service offerings; specific geographic revenue breakdown not supported by the available filing excerpts.

Source: SEC 10-K, filed 2026-02-24

Industry: Laboratory Analytical Instruments Peers: Avantor Inc Bio Rad Laboratories Inc Bio-Techne Corp Illumina Inc IQVIA Holdings Inc Mettler-toledo International Inc Repligen Corp Thermo Fisher Scientific Inc West Pharmaceutical Services Inc Waters Corp

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support